½ÃÀ庸°í¼­
»óǰÄÚµå
1376036

¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 350¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí CAGRÀº 21.01%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÒÀÓ·üÀÇ Áõ°¡¿Í ÇÔ²² Áï½Ã ³Ãµ¿ °¡´ÉÇÑ ¹èÁöÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Áúº´ °ü¸®¿¡¼­ ¼¼Æ÷ Ä¡·áÀÇ Á߿伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ ³Ãµ¿ º¸Á¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºñ¿ë È¿À²ÀûÀÎ µ¿°áº¸Á¸ ¹èÁö¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÷´Ü ÀǾàǰ °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ÀÇ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. »ì¾ÆÀÖ´Â ¼¼Æ÷¸¦ ³Ãµ¿ º¸Á¸ÇÒ ¶§ ºùÁ¤ ¹ß»ýÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ´Â Áï½Ã »ç¿ë °¡´ÉÇÑ ¹èÁö´Â ¿¬±¸ Ä¿¹Â´ÏƼ¿¡¼­ Á¡Á¡ ´õ ¸¹ÀÌ Ã¤Åõǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼Æ÷ ±â¹Ý ÀǾàǰÀÇ ÀαⰡ ³ô¾ÆÁü¿¡ µû¶ó Á¦Á¶¾÷üµéÀÌ ½É°¢ÇÑ Áúº´À» Ä¡·áÇÒ ¼ö Àִ ÷´Ü ¹ÙÀÌ¿ÀÀǾàǰÀ» °³¹ßÇϱâ À§ÇØ ´ë±Ô¸ð ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ³Ãµ¿ º¸Á¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

COVID-19 ¹é½ÅÀÇ ±Þ¼ÓÇÑ ¿¬±¸°³¹ß°ú »ó¾÷Àû Á¦Á¶ Ȱµ¿ÀÇ Áö¼ÓÀº »ý¹°ÇÐÀû Á¦Á¦ ±â¹Ý ¿¬±¸ Ȱµ¿¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÚ±ØÀ» ÁÖ¾î ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÀå ¼ö¿äÀÇ Áõ°¡, °æÀï»ç °£ÀÇ °æÀï ½ÉÈ­, ÃÖÁ¾»ç¿ëÀÚÀÇ ´Ù¾çÇÑ ¿ëµµ´Â ¸ðµÎ ³Ãµ¿ º¸Á¸¿ë µ¿°á ¹èÁöÀÇ Ã³¹æ °³¹ß¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÇöÀç ¸ÂÃãÇüÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, Merck KGaAÀÇ ½Ã±×¸¶ ¾Ëµå¸®Ä¡(Sigma Aldrich) ºê·£µå´Â ÃÖÀûÀÇ È¸¼ö ¹× ¼¼Æ÷ »ýÁ¸À» º¸ÀåÇÏ´Â Áٱ⼼Æ÷¿ë ³Ãµ¿¹èÁö ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ³Ãµ¿ ¸Åü´Â ±âÁ¸ ³Ãµ¿ °øÁ¤º¸´Ù ´ÙÀç´Ù´ÉÇϰí, Áï½Ã »ç¿ëÇÒ ¼ö ÀÖ°í, Àú·ÅÇϱ⠶§¹®¿¡ ÃÖÁ¾»ç¿ëÀÚµé »çÀÌ¿¡¼­ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ³Ãµ¿ °øÁ¤Àº ¾×ü Áú¼Ò¸¦ »ç¿ëÇØ¾ß Çϱ⠶§¹®¿¡ ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á°¡ Å®´Ï´Ù. Áú¼Ò »ç¿ëÀÇ ´Ù¸¥ ´ÜÁ¡À¸·Î´Â 2Â÷ ¿À¿° °¡´É¼º, ³ôÀº ¿î¿µ ºñ¿ë, ´ë±â Áß »ê¼Ò ´ëü¿¡ µû¸¥ Áú½Ä À§Çè µîÀÌ ÀÖ½À´Ï´Ù. ±× °á°ú ÃÖ±Ù ¸î ³â µ¿¾È Áï½Ã »ç¿ë °¡´ÉÇÑ ³Ãµ¿ ¸ÅüÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ¿© ³Ãµ¿ º¸Á¸ ½ÃÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ³Ãµ¿¹èÁö Á¦Á¦ ¹× ³Ãµ¿º¸Á¸ ±â¼ú ¿¬±¸°³¹ß, Á¶Á÷°øÇÐ, ¼¼Æ÷Ä¡·á, Áٱ⼼Æ÷ ¿¬±¸ µîÀÇ ºÐ¾ß¿¡¼­ ³Ãµ¿º¸Á¸ ³Ãµ¿¹èÁö ÀÀ¿ëºÐ¾ßÀÇ È°¿ëÀÌ ½ÃÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Àç»ýÀÇ·á ¹× ¼¼Æ÷ ±â¹Ý ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ¿ìÈ£ÀûÀÎ ±ÔÁ¦´Â ¼¼°è ½ÃÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î´Â ¼Ò¸ðǰ ºÎ¹®ÀÌ 2023³â 40.76%ÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¼¼Æ÷ ±â¹Ý Ä¡·á ¹× º¸Á¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÃÖÁ¾»ç¿ëÀÚÀÇ ¼Ò¸ðǰ À籸¸Å·Î ÀÎÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
  • ¿ëµµº°·Î´Â Áٱ⼼Æ÷°¡ 2023³â 35.80%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÇ·áÁø°ú °úÇÐÀÚµéÀÇ Áٱ⼼Æ÷ ¿¬±¸ Áõ°¡¿Í ÷´Ü Ä¡·á¹ý °³¹ßÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì Áö¿ªÀº 2023³â 40.26%ÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÁÖ·Î ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚÀÇ Á¸Àç¿Í ÀÌ Áö¿ªÀÇ ÀÇ·á ºñ¿ë »ó½Â¿¡ ±âÀÎÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ³­ÀÚ µ¿°á ÁÖ±â Áõ°¡
    • Áٱ⼼Æ÷ ¿¬±¸°³¹ß Ȱµ¿ Áõ°¡
    • ¹ÙÀÌ¿À¹ðÅ© ¼ö Áõ°¡¿Í ¸ÂÃãÇü ÀÇ·á ¼ö¿ä ±ÞÁõ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ³ôÀº ¼³ºñºñ
  • »ç¾÷ ȯ°æ ºÐ¼®
    • PESTEL ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦4Àå Á¦Ç° ºñÁö´Ï½º ºÐ¼®

  • ¼¼°èÀÇ ¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ¼¼Æ÷ µ¿°á ¹èÁö
    • ¼¼Æ÷ µ¿°á ¹èÁö ½ÃÀå, 2018-2030³â
    • ¿¡Æ¿·»±Û¸®ÄÝ
    • µð¸ÞÆ¿¼úÆø½Ãµå
    • ±Û¸®¼¼·Ñ
    • ±âŸ
  • Àåºñ
    • ±â±â ½ÃÀå, 2018-2030³â
    • ³Ãµ¿°í
    • º¸À°±â
    • ¾×ü Áú¼Ò °ø±Þ ÅÊÅ©
  • ¼Ò¸ðǰ
    • ¼Ò¸ðǰ ½ÃÀå, 2018-2030³â
    • ±ØÀú¿Â ¹ÙÀ̾Ë
    • ±ØÀú¿Â Æ©ºê
    • Äð·¯ ¹Ú½º¡¤ÄÁÅ×À̳Ê
    • ±âŸ

Á¦5Àå ¿ëµµ ºñÁö´Ï½º ºÐ¼®

  • ¼¼°èÀÇ ¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • Áٱ⼼Æ÷
  • ³­¸ð¼¼Æ÷¿Í ¹è¼¼Æ÷
  • Á¤ÀÚ¼¼Æ÷
  • °£¼¼Æ÷
  • ±âŸ

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁö´Ï½º ºÐ¼®

  • ¼¼°èÀÇ ¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¹ÙÀÌ¿ÀÀǾàǰ ¹× Á¦¾àȸ»ç
    • ¹ÙÀÌ¿ÀÀǾàǰ ¹× Á¦¾àȸ»ç ½ÃÀå, 2018-2030³â
  • Á¶»ç±â°ü
    • Á¶»ç±â°ü ½ÃÀå, 2018-2030³â
  • ¹ÙÀÌ¿À¹ðÅ©
    • ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå, 2018-2030³â
  • ü¿Ü¼öÁ¤ Ŭ¸®´Ð
    • ü¿Ü¼öÁ¤ Ŭ¸®´Ð ½ÃÀå, 2018-2030³â
  • ±âŸ
    • ±âŸ ½ÃÀå, 2018-2030³â

Á¦7Àå Áö¿ª ºñÁö´Ï½º ºÐ¼®

  • ¼¼°èÀÇ ¼¼Æ÷ µ¿°áº¸Á¸ ½ÃÀå Á¡À¯À²(Áö¿ªº°, 2023³â ¹× 2030³â)
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï »óȲ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå Á¡À¯À²/Æ÷Áö¼Ç Á¡À¯À² ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä¡¤¸®½ºÆ®
    • Thermo Fisher Scientific Inc.
    • PromoCell GmbH
    • Merck KGaA
    • Sartorius AG
    • Lonza
    • Corning Incorporated
    • Creative Biolabs
    • BioLife Solutions Inc.
    • Danaher
    • HiMedia Laboratories
ksm 23.11.17

Cell Cryopreservation Market Growth & Trends:

The global cell cryopreservation market size is expected to reach USD 35.03 billion by 2030 with a CAGR of 21.01%, according to a new report by Grand View Research, Inc.. The increased use of ready-to-freeze media, combined with rising infertility rates, is driving demand for these products. Furthermore, the rising prevalence of chronic diseases, as well as the increasing importance of cell therapy for disease management, have prompted the demand for effective cryopreservation.

The increased demand for cost-effective cryopreservation medium has stemmed from increased research & development (R&D) activities to create advanced medicines. The capacity of ready-to-use media to decrease the development of ice crystals while cryopreserving live cells led to its increasing adoption among the research community. Furthermore, the rising popularity of cell-based drugs has resulted in massive investments from manufacturers to develop sophisticated biopharmaceuticals for serious medical conditions, which will propel the demand for cryopreservation and further boost the market growth.

The rapid R&D for the COVID-19 vaccine, as well as its continued commercial manufacturing activities, have also significantly impacted and stimulated biologics-based research activities, resulting in increased market growth. Furthermore, the growing market demand, increased competition among competitors, and diverse applications by end-users have all contributed to developments in cryopreservation freezing media formulations, which are now even accessible on a custom basis. For example, Merck KGaA's Sigma Aldrich brand provides frozen media solutions for stem cell applications while ensuring optimal recovery and cell survival, thus, propelling the cryopreservation market growth.

The versatility, ready-to-use, and inexpensive cost of these media over traditional freezing processes have resulted in widespread adoption among end-users. Traditional freezing processes necessitate the use of liquid nitrogen, which has significant safety concerns. Other disadvantages of nitrogen use include the potential of cross-contamination, high operating costs, and the risk of asphyxiation due to the displacement of atmospheric oxygen. As a result, the use of ready-to-use freezing media has grown in recent years which further boosts the cryopreservation market.

Additionally, developments in freezing media formulation and cryopreservation techniques, as well as leveraging cryopreservation freezing media applications in fields such as tissue engineering, cellular treatment, and stem cell research, have driven the market at a substantial rate. Favorable government regulations for regenerative medicine & cell-based research are expected to further boost the global market.

Cell Cryopreservation Market Report Highlights:

  • Based on product, the consumables segment accounted for the largest market share of 40.76% in 2023. The market is expanding due to the growing demand for cell based-therapies & preservation, and re-purchasing of consumables by end-users
  • Based on application, stem cells accounted for the largest market share of 35.80% in 2023. Increased stem cell research and the development of advanced therapies by medical professionals and scientists is predicted to drive the market growth
  • North America held the largest market share of 40.26% in 2023. This is mostly due to the presence of major market participants and the rising cost of healthcare in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End-user Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Increase in the number of egg-freezing cycles
    • 3.3.2. Increase in research and development activities for stem cells
    • 3.3.3. Rise in the number of biobanks and surge in demand for personalized medicines
  • 3.4. Market Restraint Analysis
    • 3.4.1. High cost of equipment
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Global Cell Cryopreservation Market: Product Movement Analysis
  • 4.2. Cell Freezing Media
    • 4.2.1. Cell Freezing Media Market, 2018 - 2030 (USD Million)
    • 4.2.2. Ethylene Glycol
      • 4.2.2.1. Ethylene Glycol Market, 2018 - 2030 (USD Million)
    • 4.2.3. Dimethyl Sulfoxide
      • 4.2.3.1. Dimethyl Sulfoxide Market, 2018 - 2030 (USD Million)
    • 4.2.4. Glycerol
      • 4.2.4.1. Glycerol Market, 2018 - 2030 (USD Million)
    • 4.2.5. Others
      • 4.2.5.1. Others Market, 2018 - 2030 (USD Million)
  • 4.3. Equipment
    • 4.3.1. Equipment Market, 2018 - 2030 (USD Million)
    • 4.3.2. Freezers
      • 4.3.2.1. Freezers Market, 2018 - 2030 (USD Million)
    • 4.3.3. Incubators
      • 4.3.3.1. Incubators Market, 2018 - 2030 (USD Million)
    • 4.3.4. Liquid Nitrogen Supply Tanks
      • 4.3.4.1. Liquid Nitrogen Supply Tanks Market, 2018 - 2030 (USD Million)
  • 4.4. Consumables
    • 4.4.1. Consumables Market, 2018 - 2030 (USD Million)
    • 4.4.2. Cryogenic vials
      • 4.4.2.1. Cryogenic Vials Market, 2018 - 2030 (USD Million)
    • 4.4.3. Cryogenic tubes
      • 4.4.3.1. Cryogenic Tubes Market, 2018 - 2030 (USD Million)
    • 4.4.4. Cooler boxes/containers
      • 4.4.4.1. Cooler boxes/containers Market, 2018 - 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Global Cell Cryopreservation Market: Application Movement Analysis
  • 5.2. Stem Cells
    • 5.2.1. Stem Cells Market, 2018 - 2030 (USD Million)
  • 5.3. Oocytes and Embryotic cells
    • 5.3.1. Oocytes and Embryotic Cells Market, 2018 - 2030 (USD Million)
  • 5.4. Sperm Cells
    • 5.4.1. Sperm Cells Market, 2018 - 2030 (USD Million)
  • 5.5. Hepatocytes
    • 5.5.1. Hepatocytes Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-Use Business Analysis

  • 6.1. Global Cell Cryopreservation Market: End-Use Movement Analysis
  • 6.2. Biopharmaceutical & Pharmaceutical Companies
    • 6.2.1. Biopharmaceutical & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 6.3. Research Institutes
    • 6.3.1. Research Institutes Market, 2018 - 2030 (USD Million)
  • 6.4. Biobanks
    • 6.4.1. Biobanks Market, 2018 - 2030 (USD Million)
  • 6.5. IVF clinics
    • 6.5.1. IVF Clinics Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Global Cell Cryopreservation Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Target Disease Prevalence
      • 7.2.2.4. U.S. Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Target Disease Prevalence
      • 7.2.3.4. Canada Cell Cryopreservation Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Target Disease Prevalence
      • 7.3.2.4. Germany Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Target Disease Prevalence
      • 7.3.3.4. UK Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Target Disease Prevalence
      • 7.3.4.4. France Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Target Disease Prevalence
      • 7.3.5.4. Italy Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Target Disease Prevalence
      • 7.3.6.4. Spain Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Target Disease Prevalence
      • 7.3.7.4. Denmark Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Target Disease Prevalence
      • 7.3.8.4. Sweden Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Target Disease Prevalence
      • 7.3.9.4. Norway Cell Cryopreservation Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Target Disease Prevalence
      • 7.4.2.4. Japan Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Target Disease Prevalence
      • 7.4.3.4. China Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Target Disease Prevalence
      • 7.4.4.4. India Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Target Disease Prevalence
      • 7.4.5.4. South Korea Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Target Disease Prevalence
      • 7.4.6.4. Australia Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Target Disease Prevalence
      • 7.4.7.4. Thailand Cell Cryopreservation Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Target Disease Prevalence
      • 7.5.2.4. Brazil Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Target Disease Prevalence
      • 7.5.3.4. Mexico Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Target Disease Prevalence
      • 7.5.4.4. Argentina Cell Cryopreservation Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Target Disease Prevalence
      • 7.6.2.4. South Africa Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Target Disease Prevalence
      • 7.6.3.4. Saudi Arabia Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Target Disease Prevalence
      • 7.6.4.4. UAE Cell Cryopreservation Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Target Disease Prevalence
      • 7.6.5.4. Kuwait Cell Cryopreservation Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market/Position Share Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. PromoCell GmbH
      • 8.4.2.1. Overview
      • 8.4.2.2. Product Benchmarking
      • 8.4.2.3. Strategic Initiatives
    • 8.4.3. Merck KGaA
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Sartorius AG
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Lonza
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Corning Incorporated
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Creative Biolabs
      • 8.4.7.1. Overview
      • 8.4.7.2. Product Benchmarking
      • 8.4.7.3. Strategic Initiatives
    • 8.4.8. BioLife Solutions Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Danaher
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. HiMedia Laboratories
      • 8.4.10.1. Overview
      • 8.4.10.2. Product Benchmarking
      • 8.4.10.3. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦